[
    {
        "content": "* Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S",
        "date": "10262017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin reports Q3 loss $0.07/shr "
    },
    {
        "content": "* FDA grants Breakthrough Therapy Designation for BioMarin's valoctocogene roxaparvovec (formerly BMN 270)  an investigational gene therapy for hemophilia A",
        "date": "10262017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "BRIEF-FDA grants Breakthrough Therapy Designation for BioMarin's gene therapy for hemophilia A "
    },
    {
        "content": "* Biomarin Pharmaceutical says \u200don September 28  2017  board of directors of increased size of board from nine to ten members\u200b - SEC filing Source: (http://bit.ly/2yWOHiP) Further company coverage:",
        "date": "10032017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin Pharmaceutical: Increased board size from nine to ten members\u200b "
    },
    {
        "content": "* FDA not currently planning to hold advisory committee meeting for Biomarin's Pegvaliase Biologics License Application (BLA)",
        "date": "09142017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-FDA not planning to hold advisory committee meeting for Biomarin's Pegvaliase BLA "
    },
    {
        "content": "* FDA accepts Biomarin's Pegvaliase Biologics License Application (bla) and grants priority review designation",
        "date": "08292017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-FDA accepts Biomarin's Pegvaliase Biologics License Application "
    },
    {
        "content": "* BioMarin announces offering of $450 million of 0.599% senior subordinated convertible notes due 2024",
        "date": "08082017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-BioMarin announces offering of $450 mln of 0.599 pct senior convertible notes "
    },
    {
        "content": "* Biomarin announces offering of $450 million of senior subordinated convertible notes due 2024",
        "date": "08072017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin announces offering of $450 mln of senior subordinated convertible notes due 2024 "
    },
    {
        "content": "* BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270  its investigational Gene Therapy For Hemophilia A  into phase 3 studies",
        "date": "08022017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270  its investigational gene therapy for Hemophilia A  into phase 3 studies "
    },
    {
        "content": "* Sarepta Therapeutics and Biomarin Pharmaceutical Inc. Announce execution of a global settlement and a license agreement resolving exon skipping patent litigation",
        "date": "07182017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Sarepta and Biomarin report execution of global settlement "
    },
    {
        "content": "* Biomarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg dose maintains average factor VIII levels within normal range for over one year",
        "date": "07112017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin Pharmaceutical says plans to initiate phase 3 registrational study in Q4 2017 for BMN 270 "
    },
    {
        "content": "* BioMarin submits pegvaliase biologics license application (BLA) to the U.S. FDA for treatment of phenylketonuria (PKU)",
        "date": "06302017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-BioMarin submits pegvaliase Biologics License Application to the U.S. FDA for treatment of phenylketonuria "
    },
    {
        "content": "* Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S",
        "date": "05042017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin Q1 GAAP loss per share $0.09 "
    },
    {
        "content": "Biomarin Pharmaceuticals Inc said the annual price for its drug  which won U.S. approval on Thursday  to treat a rare and fatal type of pediatric brain disease is expected to be $486 000 after mandatory government discounts and rebates.",
        "date": "04272017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "Biomarin sets high price for rare pediatric brain disease drug "
    },
    {
        "content": "April 27 Biomarin Pharmaceuticals Inc said the annual price for its drug  which won U.S. approval on Thursday  to treat a rare and fatal type of pediatric brain disease is expected to be $486 000 after mandatory government discounts and rebates.",
        "date": "04272017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "UPDATE 2-Biomarin sets high price for rare pediatric brain disease drug "
    },
    {
        "content": "* Biomarin Pharmaceuticals says expects to begin shipping just approved Brineura within 6 weeks",
        "date": "04272017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin says Brineura U.S. annual price $486 000 "
    },
    {
        "content": "April 27 The United States Food and Drug Administration said on Thursday it had approved Biomarin Pharmaceutical Inc's drug to treat a type of Batten disease  a rare disorder that mainly affects the nervous system and is ultimately fatal.",
        "date": "04272017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "U.S. FDA approves Biomarin's Batten disease drug "
    },
    {
        "content": "* Granted approval of Brineura to Biomarin Pharmaceutical Inc",
        "date": "04272017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "BRIEF-U.S. FDA says granted approval of Brineura to Biomarin Pharmaceutical "
    },
    {
        "content": "* Biomarin announces Kuvan (sapropterin dihydrochloride) patent challenge settlement",
        "date": "04132017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin announces Kuvan patent challenge settlement "
    },
    {
        "content": "* Biomarin announces fourth quarter and full year 2016 financial results",
        "date": "02232017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin reports Q4 GAAP loss per share $0.53 "
    },
    {
        "content": "* Jennison Associates Llc reports 5.4 percent passive stake in Biomarin Pharmaceutical Inc as of Dec 31  2016- sec filing  Source text - http://bit.ly/2jIyNQd Further company coverage:",
        "date": "02022017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Jennison Associates Llc reports 5.4 pct passive stake in Biomarin Pharmaceutical "
    },
    {
        "content": "Jan 8 BioMarin Pharmaceutical Inc  announced on Sunday what it called \"positive interim results\" from its study of a gene therapy treatment for severe hemophilia.",
        "date": "01092017",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BioMarin Pharma cites positive results for hemophilia treatment "
    },
    {
        "content": "* Q3 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S",
        "date": "10272016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-BioMarin announces Q3 GAAP loss per share of $0.26 "
    },
    {
        "content": "* Biomarin Pharmaceutical - Provided update on phase 2 study of vosoritide  analog of C-type Natriuretic Peptide (CNP)  in children with achondroplasia",
        "date": "10192016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin Pharmaceutical provided update on mod-stage study of vosoritide "
    },
    {
        "content": "* UK regulatory agency approves continued enrollment in Biomarin phase 1/2 study  of BMN 270 in Hemophilia a",
        "date": "10132016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-UK regulatory agency approves continued enrollment in Biomarin phase 1/2 study "
    },
    {
        "content": "* To seek review of patent trial and appeal board ruling  for composition of matter claims related to exon 51 skipping antisense oligonucleotides",
        "date": "09212016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-BioMarin reviews status of Exon 51 composition of matter "
    },
    {
        "content": "* BioMarin announces update to Brineura (cerliponase alfa) program  for treatment of CLN2 disease  a form of batten disease",
        "date": "09062016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-BioMarin announces update to Brineura program "
    },
    {
        "content": "* Biomarin announces pricing of public offering of common stock",
        "date": "08092016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin Pharmaceutical announces pricing of public offering of common stock "
    },
    {
        "content": "* Files for potential mixed shelf offering; size not disclosed - SEC filing  Source text: http://bit.ly/2b45rwC  Further company coverage:",
        "date": "08082016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin Pharmaceutical files for potential mixed shelf offering "
    },
    {
        "content": "* Says offering of 7.5 million shares of its common stock in an underwritten public offering  Source text for Eikon:  Further company coverage:",
        "date": "08082016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin says offering of 7.5 mln shares of stock "
    },
    {
        "content": "* Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S",
        "date": "08042016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin Pharmaceutical Q2 GAAP loss per share $2.61 "
    },
    {
        "content": "* FDA accepts BLA for BioMarin's Cerliponase Alfa for CLN2 disease  form of Batten disease  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "07272016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-FDA Accepts BLA for BioMarin's Cerliponase Alfa for CLN2 Disease "
    },
    {
        "content": "* Biomarin to provide updated data for BMN 270 in Hemophilia A in late breaking oral presentation at the World Federation of Hemophilia (WFH) 2016 World Congress July 27th  Source text for Eikon:  Further company coverage:",
        "date": "07212016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-BioMarin to provide updated data on Hemophilia drug "
    },
    {
        "content": "* Biomarin appoints two biopharmaceutical veterans to board of directors  Willard Dere  M.D. And Kathryn E. Falberg  Source text for Eikon:  Further company coverage:",
        "date": "07182016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin makes board appointments "
    },
    {
        "content": "* Biomarin announces withdrawal of market authorization application for Kyndrisa\u007f (drisapersen) in Europe",
        "date": "05312016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin withdraws market authorization application for Kyndrisa in Europe "
    },
    {
        "content": "* Biomarin announces ema grants accelerated assessment for  cerliponase alfa  experimental treatment for a form of batten disease",
        "date": "05032016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin Pharmaceutical announces EMA grants accelerated assessment "
    },
    {
        "content": "* Q1 earnings per share view $-0.79 -- Thomson Reuters I/B/E/S",
        "date": "04282016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin posts Q1 GAAP loss per share $0.53 "
    },
    {
        "content": "* Q1 earnings per share view $-0.79 -- Thomson Reuters I/B/E/S",
        "date": "04282016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin Q1 gaap loss per share $0.53 "
    },
    {
        "content": "* Biomarin enrolls first patient in phase 1/2 trial of NAGLU fusion protein BMN 250 for treatment of MPS IIIB (sanfilippo B syndrome)",
        "date": "04212016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin enrolls first patient in early study of BMN 250 for sanfilippo B syndrome "
    },
    {
        "content": "* Biomarin provides program update on Vosoritide in Achondroplasia",
        "date": "04202016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin provides program update on Vosoritide in Achondroplasia "
    },
    {
        "content": "* Biomarin provides encouraging preliminary data on first 8 patients in hemophilia a gene therapy program",
        "date": "04202016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin provides preliminary data on first 8 patients in Hemophilia A gene therapy program "
    },
    {
        "content": "* Receives European orphan drug designation for bmn 270  first investigational aav-factor viii gene therapy for patients with hemophilia a  Source text for Eikon:  Further company coverage:",
        "date": "03242016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BRIEF-Biomarin- gets European orphan drug designation for Gene Therapy drug for Hemophilia A "
    },
    {
        "content": "BioMarin Pharmaceutical Inc's drug met a study's main goal of reducing a toxic buildup of an amino acid in the blood of patients with a genetic disorder  but did not show enough benefit in related inattention and mood complications.",
        "date": "03212016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BioMarin drug fails to show inattention  mood benefit in study "
    },
    {
        "content": "* Stock falls as much as 6 pct   (Adds details from conference call; updates shares)",
        "date": "03212016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "UPDATE 3-BioMarin drug fails to show inattention  mood benefit in study "
    },
    {
        "content": "The U.S. Food and Drug Administration rejected BioMarin Pharmaceutical Inc's drug to treat a rare muscle-wasting disorder  shifting investor focus to Sarepta Therapeutics Inc's rival drug in development.",
        "date": "01142016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "FDA rejects BioMarin's muscle wasting drug; Sarepta drug in focus "
    },
    {
        "content": "SAN FRANCISCO BioMarin Pharmaceutical is expecting U.S. regulators to take action this month on its drug to treat a fatal muscle-wasting disease but is also eyeing the European market  its chief executive officer said in an interview.",
        "date": "01112016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BioMarin CEO  waiting on FDA on Duchenne drug  eyes Europe "
    },
    {
        "content": "Jan 8 Akashi Therapeutics Inc  a U.S.-based biotech funded by DMD patient foundations  said it would get up to $100 million under a partnership with Germany's Grunenthal SA for developing a drug for the muscle-wasting disorder.",
        "date": "01082016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "Patient-funded biotech in $100 mln funding deal for DMD drug "
    },
    {
        "content": "* Sarepta's rival drug to be reviewed next week   (Recasts; adds analyst comments)",
        "date": "01142016",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "UPDATE 3-FDA rejects BioMarin's muscle wasting drug; Sarepta drug in focus "
    },
    {
        "content": "The U.S. Food and Drug Administration pushed back its deadline to decide on drug developer BioMarin Pharmaceutical Inc's lead drug  not rejecting it outright  making shareholders optimistic.",
        "date": "12182015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "FDA delays BioMarin drug approval  gives investors hope "
    },
    {
        "content": "* Delay could mean higher chances of approval - analysts   (Adds analysts' comments; updates shares)",
        "date": "12182015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "UPDATE 2-FDA delays BioMarin drug approval  gives investors hope "
    },
    {
        "content": "Dec 18 Drug developer BioMarin Pharmaceutical Inc said it was notified by the U.S. Food and Drug Administration that it would not be able to decide on the marketing of the company's lead drug as scheduled.",
        "date": "12182015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "BioMarin says FDA to delay deciding on approval of DMD drug "
    },
    {
        "content": "A panel of outside advisers to the U.S. Food and Drug Administration indicated that efficacy data from BioMarin Pharmaceutical Inc on its experimental drug for treating a muscle wastage disorder was not persuasive enough to warrant approval.",
        "date": "11242015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "FDA panel says BioMarin DMD drug data not persuasive enough "
    },
    {
        "content": "Nov 24 A panel of outside advisers to the U.S. Food and Drug Administration indicated that efficacy data from BioMarin Pharmaceutical Inc on its experimental drug for treating a muscle wastage disorder was not persuasive enough to warrant approval.",
        "date": "11242015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "UPDATE 2-FDA panel says BioMarin DMD drug data not persuasive enough "
    },
    {
        "content": "* Rival Sarepta's shares jump 34 pct   (Adds details  analyst quote  updates shares)",
        "date": "11202015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "UPDATE 2-Data does not support nod for BioMarin's DMD drug - FDA staff "
    },
    {
        "content": "FRANKFURT  Oct 1 Germany's Merck KGaA  said it agreed to return to BioMarin Pharmaceutical Inc  the rights to the Kuvan drug against rare genetic disorder PKU as it seeks to focus on cancer  immunology and neurology.",
        "date": "10012015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "Germany's Merck sells rights to Kuvan back to BioMarin Pharma "
    },
    {
        "content": "BioMarin Pharmaceutical Inc said its experimental drug was effective in improving growth in children with the most common form of dwarfism in a mid-stage study.",
        "date": "06172015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "BioMarin's dwarfism drug improves growth in a mid-stage study "
    },
    {
        "content": "June 17 BioMarin Pharmaceutical Inc  said its experimental drug was effective in improving growth in children with the most common form of dwarfism in a mid-stage study.",
        "date": "06172015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "UPDATE 1-BioMarin's dwarfism drug improves growth in a mid-stage study "
    },
    {
        "content": "June 17 BioMarin Pharmaceutical Inc  said its experimental drug was effective in improving growth in children with the most common form of dwarfism in a mid-stage study.",
        "date": "06172015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "BioMarin's dwarfism treatment improves growth in mid-stage study "
    },
    {
        "content": "Feb 23 The following bids  mergers  acquisitions and disposals were reported by 2115 GMT on Monday:",
        "date": "02232015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "topStory",
        "symbol": "BMRN",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "Rare disease drugmaker PTC Therapeutics Inc  is exploring a potential sale amid takeover interest from several pharmaceutical companies  including Shire Plc  and BioMarin Pharmaceutical Inc   according to people familiar with the matter.",
        "date": "02232015",
        "name": "BioMarin Pharmaceutical Inc",
        "news_type": "normal",
        "symbol": "BMRN",
        "title": "Exclusive: Rare disease drugmaker PTC Therapeutics explores sale - sources "
    }
]